Analyst Price Targets — ZYME
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 12:08 pm | — | Evercore ISI | $48.00 | $24.25 | TheFly | Zymeworks price target raised to $48 from $33 at Evercore ISI |
| December 17, 2025 11:16 am | Asthika Goonewardene | Truist Financial | $40.00 | $25.85 | TheFly | Zymeworks initiated with a Buy at Truist |
| December 12, 2025 10:20 am | — | Wells Fargo | $33.00 | $24.93 | TheFly | Zymeworks upgraded to Overweight from Equal Weight at Wells Fargo |
| December 3, 2025 10:03 am | — | JMP Securities | $32.00 | $25.10 | TheFly | Zymeworks initiated with an Outperform at Citizens JMP |
| November 19, 2025 10:31 am | Eva Verdejo | Wells Fargo | $25.00 | $22.99 | StreetInsider | Zymeworks (ZYME) PT Raised to $25 at Wells Fargo |
| November 19, 2025 9:27 am | Stephen Willey | Stifel Nicolaus | $40.00 | $22.99 | StreetInsider | Zymeworks (ZYME) PT Raised to $40 at Stifel |
| November 17, 2025 7:36 pm | Andrew Berens | Leerink Partners | $37.00 | $23.90 | TheFly | Zymeworks price target raised to $37 from $24 at Leerink |
| October 14, 2025 10:07 am | Robert Burns | H.C. Wainwright | $26.00 | $18.11 | TheFly | Zymeworks upgraded to Buy from Neutral at H.C. Wainwright |
| November 21, 2024 2:22 pm | Andrew Berens | Leerink Partners | $26.00 | $13.68 | StreetInsider | Zymeworks (ZYME) PT Raised to $26 at Leerink Partners |
| November 1, 2024 9:13 am | Derek Archila | Wells Fargo | $12.00 | $13.28 | StreetInsider | Wells Fargo Downgrades Zymeworks (ZYME) to Equal Weight |
Latest News for ZYME
Six poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple solid tumor models New programs include Ly6E, CLDN18.2, and PTK7-targeting ADCs, as well as novel payload and platform innovations New clinical data from Phase 1 trial of ZW191 to be presented…
VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a…
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer
Capricorn Fund Managers Ltd purchased a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,022,840 shares of the company's stock, valued at approximately $26,931,000. Zymeworks makes up about 6.5% of
Neoleukin Therapeutics (NASDAQ: NLTX - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends. Institutional and Insider Ownership 52.4% of Neoleukin Therapeutics
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZYME.
U.S. House Trading
No House trades found for ZYME.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.